Antidepressants, widely prescribed for the treatment of depression and other mental health conditions, have been linked to a range of potential long-term risks and side effects that warrant careful consideration by both patients and healthcare providers. Experts emphasize that the drugs’ mechanism—primarily targeting serotonin levels in the brain—may also affect other parts of the body where serotonin plays a critical role, such as bones, joints, muscles, and the peripheral nervous system.
Common side effects experienced shortly after starting antidepressants include emotional blunting, changes in sleep patterns, gastrointestinal issues, and weight gain. Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants, are also associated with sexual dysfunction and reduced libido. Other antidepressant classes, such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants, increase levels of noradrenaline, a hormone linked to “fight or flight” responses, which may raise heart rate and blood pressure and contribute to higher cholesterol and narrowed blood vessels.
Of particular concern is the potential impact on cardiac health. Antidepressants may prolong the QT interval—a measurement on an electrocardiogram that reflects the time the heart’s lower chambers take to contract and reset. A prolonged QT interval is associated with irregular and potentially fatal heart rhythms. A 2025 study presented at the European Society of Cardiology congress indicated that antidepressant use of between one and five years could increase the risk of sudden cardiac death by 56 percent, with longer durations corresponding to higher risks. While other factors may also play a role, experts consider these findings biologically plausible given the known effects of these medications on heart electrical activity.
Research also points to an increased risk of type 2 diabetes among antidepressant users, possibly linked partly to drug-induced weight gain and interference with blood sugar regulation. Additionally, studies have suggested a higher risk of bone fractures in people over 50 taking SSRIs or tricyclics, with risk magnitude increasing with prolonged use. The exact cause remains uncertain, although lifestyle factors commonly associated with depression—such as smoking and physical inactivity—may contribute.
The relationship between antidepressants and dementia remains unclear. While depression itself is a significant risk factor for cognitive decline, there is some evidence that older antidepressants, such as amitriptyline, could affect memory, and a 2025 Swedish study suggested that higher SSRI doses might accelerate dementia progression in affected individuals.
Another important consideration is the severity of withdrawal symptoms upon discontinuing antidepressants, which may include sensations described as "brain zaps," mood disturbances, anxiety, flu-like symptoms, agitation, and insomnia. Health professionals emphasize the necessity of tapering off these medications under medical supervision rather than stopping abruptly.
Despite these concerns, public health authorities stress the importance of continuing antidepressants unless advised otherwise by a healthcare provider, as sudden cessation can pose significant risks. Official guidance underscores that each antidepressant has unique benefits and potential risks, detailed in patient information leaflets, and patients should consult their doctors or pharmacists about any side effects.
Individual accounts highlight these risks in practice. Rachel Buckmaster, a 27-year-old scientist from Cambridgeshire, reported developing heart palpitations after five years on the SSRI citalopram prescribed for post-traumatic stress disorder. After medical evaluation, she was advised to discontinue the medication. Her palpitations ceased following withdrawal, though it took several months for her mood to stabilize. Although healthcare professionals did not explicitly confirm the antidepressant as the cause, their recommendation implied a connection. Buckmaster expressed frustration at the lack of earlier warnings about potential long-term risks.
As the dialogue around antidepressants evolves, patients and clinicians are encouraged to weigh the possible harms against the benefits, particularly given that some research questions the overall efficacy of these medications beyond placebo effects. Ongoing research and open communication remain crucial to optimizing treatment outcomes and patient safety.